Skip to content
Kalpvruksh Markets
Offline Log in

ZYDUSLIFENSEOffline

ZYDUS LIFESCIENCES · INE010B01027 · Mid Cap · #114
1,193.00+4.90 (+0.41%)last close · 05 Nov 2026
Prev close
1,188.10
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹95,716 cr
52-week range · to 05 Nov 2026860.61,245.5

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

ZYDUSLIFE is 4% below its 52-week high, above its 200-day average, ahead of Healthcare by 5.4 pts over 3 months — a Mid Cap company, #114 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · 4% below its 52-week high
  • ahead of its industry by 5.4 pts over 3 months · rank 12 of 44 in Healthcare · +8.8% vs Nifty 500
  • traded value 2.3× usual · delivery 44% vs 51% usual
  • short covering today · IV 27%, 76th pct of its year · expected move ±6.1% to expiry
  • FPI +0.2 pp · DII +0.0 pp · MF schemes in Sept 2026: 75 bought, 65 cut · no promoter pledge · insiders net bought ₹0 cr in 3 months · quarter ended 2026-09-30
  • Jun 2026 quarter: profit −36% year on year · revenue +22%
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹95,716 cr
Rank
#114
Cap band
Mid Cap
Nearest cut-off — Large / Mid
−10.06% from ₹1,06,417 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.7×
median 7,49,934
Delivered
12,62,127
Of volume
52%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+0.7%−4.8 pts—
1 month+2.9%−1.6 pts−1.0 pts
3 months+6.4%+8.8 pts+5.4 pts
6 months+27.1%+26.6 pts+14.6 pts
1 year+21.0%+24.2 pts—

Industry: Healthcare (Nifty 500 classification) · rank 12 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+2.9%
above
vs 50-day average
+3.2%
above
vs 200-day average
+14.8%
above
ATR (14)
3.1%
typical daily range
Volatility
31%
1 month, annualised
Beta
0.64
vs Nifty 500, 1 year
Traded value
2.3×
vs usual
Delivery
44%
usual 51%
From the 52-week high
−4.2%
place in range 86% (0 = at the low)

F&O

Where option open interest clusters

expiry 23 Nov 2026 · 18 days

Spot
1,193.01
Max pain
1,200
+0.6% from spot
Largest call OI (strike)
Largest put OI (strike)

Near expiry. Max pain is the strike at which option buyers’ total payout would be least; strikes with the most open interest are where positions cluster.

Volatility & expected move

ATM IV
27.6%
near expiry
IV 30
27.3%
IV rank
63
0–100 within its year
IV percentile
76
days in the year below today
Expected move to expiry
±73.15
±6.1% · one standard deviation
Range
1,120 – 1,266
Rollover
2%
futures OI in next expiries

Futures build-up, by day

all expiries' OI · today: short covering

SessionBuild-upFuture priceOI, all expiries
05 Nov 2026short covering+0.2%−2.7%
04 Nov 2026short build-up−4.0%+2.0%
03 Nov 2026short covering+0.3%−1.4%
02 Nov 2026short build-up−0.2%+4.2%
30 Oct 2026long build-up+4.3%+3.0%
29 Oct 2026short covering+0.9%−0.5%
28 Oct 2026short covering+0.8%−0.5%
27 Oct 2026short covering+0.8%−3.8%
26 Oct 2026short covering+2.9%−5.9%
23 Oct 2026long unwinding−0.8%−7.2%

From the exchanges’ F&O bhavcopies. A description of positions, not a forecast. Open interest across the market.

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters75.0%75.0%75.0%75.0%
FPI7.1%7.0% −0.16.9% −0.17.0% +0.2
Mutual funds4.7%4.9% +0.25.1% +0.26.9% +1.8
Other DII6.4%6.3%6.1% −0.24.4% −1.8
Individuals5.5%5.5%5.5% −0.15.3% −0.2
Others1.3%1.3%1.4% +0.11.4%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
3,82,067
Individuals
3,64,508

Indian passive funds’ stake

2026-06-30

Of free float
2.51%
Of all shares
0.63%
Schemes
105
Days to unwind
3.3
at 100% of volume

62,62,490 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
174
105 index · 69 active
Bought more
101
Sold some
41
FundSharesChangeDid
Edelweiss Arbitrage Fund-Reg(G)Active+3,31,200+360.8%bought
Sundaram Value Fund-Reg(IDCW)Active+83,640+243.4%bought
LIC MF Healthcare Fund-Reg(G)Active+29,543+228.0%bought
Mirae Asset Arbitrage Fund-Reg(G)Active−41,400−50.0%sold
Edelweiss Nifty Alpha Low Volatility 30 Index Fund-Reg(G)Index−18,582−46.0%sold
Nippon India Arbitrage Fund(G)Active−30,600−31.5%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 261701659587+23.6%₹6,383 cr
Aug 261612175339+15.5%₹5,161 cr
Jul 261491052482+3.6%₹4,336 cr
Jun 261411780265+8.6%₹4,131 cr
May 261291059288−6.4%₹3,683 cr
Apr 26126473244−1.9%₹3,257 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
Bought ₹0 (1)
Sold ₹0 (0)
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 40 of 64 disclosures
0 selected
19 Aug 2026Prashant Babubhai PatelPromoter GroupBuy32,577₹00.00%Others
17 Jun 2026Tushar Dhansukh ShroffKMPSell5₹6,3000.00%Buy Back
17 Jun 2026Zydus Family TrustPromoterSell63,49,542₹800 cr0.75%Buy Back
17 Jun 2026Pripan Investment Private LimitedPromoter GroupSell149₹0.19 cr0.00%Buy Back
17 Jun 2026Pankaj Ramanbhai PatelPromoter and DirectorSell124₹0.02 cr0.00%Buy Back
17 Jun 2026Pankaj Ramanbhai Patel HUFPromoter GroupSell248₹0.03 cr0.00%Buy Back
17 Jun 2026Pankaj Ramanbhai Patel (Smaller) HUFPromoter GroupSell124₹0.02 cr0.00%Buy Back
17 Jun 2026Taraben Patel Family Will TrustPromoter GroupSell124₹0.02 cr0.00%Buy Back
17 Jun 2026Sharvil Pankajbhai PatelPromoterSell124₹0.02 cr0.00%Buy Back
17 Jun 2026Shivani PatelPromoter GroupSell124₹0.02 cr0.00%Buy Back
17 Jun 2026Pritiben Pankajbhai PatelPromoter GroupSell124₹0.02 cr0.00%Buy Back
17 Jun 2026R B Patel Will Pankaj TrustPromoter GroupSell109₹0.01 cr0.00%Buy Back
17 Jun 2026Arati Rajiv Mehta Joint with Rajiv Vastupal MehtaPromoter GroupSell640₹0.08 cr0.00%Buy Back
17 Jun 2026Ritaben Yatin DesaiPromoter GroupSell209₹0.03 cr0.00%Buy Back
17 Jun 2026Mukesh Mangalbhai PatelDirectorSell98₹0.01 cr0.00%Buy Back

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
    04 Nov 2026
  • Board outcome
    Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.
    04 Nov 2026
  • Scheme / acquisition
    Update-Acquisition (including agreement to acquire)-XBRL ZYDUS LIFESCIENCES LIMITED has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
    02 Nov 2026
  • Credit rating
    Zydus Lifesciences Limited has informed the Exchange about Credit Rating
    11 Sept 2026
  • Scheme / acquisition
    Acquisition of 'to be incorporated companies'-XBRL ZYDUS LIFESCIENCES LIMITED has informed the Exchange regarding Acquisition of to be incorporated companies
    26 Aug 2026
  • Insider trade
    Zydus Lifesciences Limited has informed the Exchange regarding 'Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015'.
    25 Aug 2026

Latest shown; 8 in six months on all disclosures.

ZYDUSLIFE: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
EarlierDividend₹1Final24 Jul 202624 Jul 2026
EarlierDividend₹11Final25 Jul 202525 Jul 2025
EarlierDividend₹3Final26 Jul 202426 Jul 2024
EarlierDividend₹6Final28 Jul 202328 Jul 2023
EarlierDividend₹2.5Final28 Jul 202229 Jul 2022
EarlierBonus1:2—05 Apr 201006 Apr 2010
EarlierBonus1:1—30 Aug 200631 Aug 2006

7 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.